In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 7 of 7

TitleConsultationTypeConsultation end date
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Draft guidanceTechnology appraisal guidance
Oveporexton for treating type 1 narcolepsy [ID6622]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]Draft guidanceTechnology appraisal guidance
Ruxolitinib for treating moderate atopic dermatitis ID6602Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]Draft guidanceTechnology appraisal guidance
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]Draft guidanceTechnology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment [ID6388]Final draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All